权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Anti-biofilm activity of bacteriophage-antibiotic combinations against MRSA

噬菌体-抗生素组合对 MRSA 的抗生物膜活性

基本信息

批准号：
10285430
负责人：
Michael Joseph Rybak
金额：
$ 19.25万
依托单位：
WAYNE STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-06-10 至 2023-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10285430
关键词：
Accounting Adjuvant Age Anti-Bacterial Agents Antibiotic Resistance Antibiotic Therapy Antibiotics Bacteremia Bacteria Bacterial Antibiotic Resistance Bacteriophages Catheter-related bloodstream infection Catheters Cefazolin Cells Centers for Disease Control and Prevention (U.S.)Clinical Combined Antibiotics Combined Modality Therapy Cytolysis Daptomycin Data Development Direct Costs Dose Drug Kinetics Drug resistance Exhibits Failure Frequencies Future Generations Genotype Genus staphylococcus Goals Growth Healthcare Systems Hour Immune system In Vitro Infection Investigation Laboratories Lead Life Lytic Measures Medical Device Metabolic Microbial Biofilms Modeling Monobactams Multi-Drug Resistance Multiple Bacterial Drug Resistance Nosocomial Infections Outcome Patient Care Penetration Pharmacodynamics Phenotype Predisposition Prevention Production Public Health Regimen Reporting Research Resistance Resistance development Rifampin Secondary to Sepsis Staphylococcus aureus Supplementation Techniques Testing Therapeutic Time Treatment Failure Vancomycin Venous Virion Work alternative treatment antimicrobial attributable mortality bacterial resistance bactericide base catheter related infection cost effective therapy efficacy evaluation emerging antibiotic resistance experimental study fitness improved in vitro activity methicillin resistant Staphylococcus aureus mortality multi-drug resistant pathogen novel pathogen pharmacodynamic model prevent response standard of care synergism treatment optimization

项目摘要

Summary/Abstract Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are problematic because of the high associated treatment failures and elevated mortality rates. Staphylococci including MRSA are the major cause of medical device infections (MDIs) due to their strong capability to form biofilms. These bacterial biofilms resist host immune system and lead to antibiotic failure due to limited antibiotic penetration, bacterial tolerance and development of antibiotic resistance. Vancomycin is the recommended therapy for MRSA MDIs and daptomycin is the primary antibiotic alternative to vancomycin for these infections; however, the development of daptomycin resistance especially post vancomycin therapy has been reported with increasing frequency. Although combination therapy of vancomycin or daptomycin with beta-lactam antibiotics such as ceftaroline have demonstrated improved activity in vitro, these combinations have not shown significant enhancements in MDIs caused by Staphylococci. Therefore, due to the lack of effective MDI treatments, novel antibacterial options are critically needed. Obligately lytic bacteriophages (phages) infect bacteria, replicate within the cell, lyse the cell to release their progeny and reinitiate the infection cycle. These phages eradicate both antibiotic susceptible and resistant bacteria in planktonic and biofilm forms. The combination of phage and antibiotics have shown to re-sensitize previously multi-drug resistant bacteria to antibiotics. Synergistic and antagonistic interactions in phage-antibiotic combinations are highly dependent on the mechanism of bacterial inhibition of the antibiotic paired to the phage, bacterial host state (biofilm versus planktonic) and bacterial growth age. Here we are offering a systematic investigation of phage antibiotic combination using various standard of care antibiotics (SOC) to examine the aforementioned parameters. The proposed research is significant especially due to lack of information regarding the use of phage with SOC antibiotics against biofilm embedded MRSA strains. Our central hypothesis is that the combination of phage-antibiotic will reduce the vancomycin and daptomycin exposures required for efficacy against biofilm embedded MRSA and further prevent the emergence of antibiotic resistance. We will test our central hypothesis by first evaluating susceptibility of biofilm embedded MRSA to various phage-antibiotic combinations and then performing in vitro two-compartment PK/PD biofilm models with humanized pharmacokinetics to optimize novel phage-antibiotic combination therapies. We expect that through optimizing therapy of MRSA-biofilm infections, we will improve patient care and prolong the useful life of vancomycin and daptomycin for the management of MRSA MDIs.

摘要/文摘